Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma
Shaukat Ali, Syed Muneeb Uddin, Ayesha Ali, Fatima Anjum, Rashid Ali, Elisha Shalim, Mujtaba Khan, Iqra Ahmed, Sheikh Muhammad Muhaymin, Uzma Bukhari, Shobha Luxmi, Abdul Samad Khan, Saeed Quraishy
Abstract
The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT04521309).
Topics & Concepts
Convalescent plasmaVirologyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibody2019-20 coronavirus outbreakImmunologyMedicineBiologyInfectious disease (medical specialty)OutbreakPathologyDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPhagocytosis and Immune Regulation